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ABSTRACT
We present a patient with thyroid cancer and hypopituitarism who required recombinant human thyrotropin(rhTSH) for 131I scanning with respect to subsequent therapy. The thyroid cancer had been unknown until cen¬
tral neurological symptoms developed, leading to the diagnosis of a huge metastasis to the sella that was the only
manifestation of metastatic spread. The failure to generate endogenous thyrotropin (TSH) was overcome by the
use of rhTSH for performing a 131I test. Unfortunately, the 131I uptake was not sufficient for therapy. This sub¬ject is the first reported case who required the application of rhTSH due to a single thyroid cancer metastasis in
the sella region with secondary failure to generate endogenous TSH.
INTRODUCTION
Metastatic thyroid cancer with iodide transport ac¬tivity should be treated by radioiodine. For optimal
sensitivity of the 131I uptake test and maximal therapeutic
uptake, stimulation of any residual thyroid tissue by high
thyrotropin (TSH) levels is required (1). This has usually
been achieved by thyroid hormone withdrawal causing se¬
vere hypothyroidism (2). The application of recombinant
human thyrotropin (rhTSH) instead of hormone with¬
drawal has been shown to be safe and effective (3,4). In
this article, we report (1) the first case of a huge single thy¬
roid cancer metastasis to the sella and (2) the usefulness of
rhTSH in a case with failure to generate endogenous TSH.
CASE REPORT
A 68-year-old woman presented with severe vision loss
that had been developing for the past 8 months. She gave
a history of frontal accentuated headaches that had been
progressive for 3 years. In the last 2 years she experienced
additional diplopia in varying grades. Recently, a person¬
ality change occurred with increased communicativeness,
being hot-tempered, and sometimes confused. She reported
four thyroid operations between 1982 and 1994 in Ka¬
zakhstan; no diagnosis or histological findings were avail¬
able. She had no hormone substitution or therapy.
On physical examination, the sight was reduced to fin¬
ger recognition on the right and to movement vision on
the left eye. Her voice was aphonie; no other neurological
defects were detected. Magnetic resonance imaging (MRI)
revealed a large solid tumor in the sella region with de¬
struction of the surrounding osseous structures, and the
optic chiasm was no longer identifiable (Fig. 1). There was
no diabetes insipidus, but the anterior pituitary function
tests revealed hypopituitarism (Table 1). Preoperatively,
various stimulation tests for the pituitary function reserve
were performed (details given in Table 1). The tentative di¬
agnosis was pituitary adenoma with the differential diag¬
noses of chordoma, chondroma or meningioma.
To obtain a rapid decompression of the optic nerves and
chiasm, transsphenoidal surgery was done as a first-step
procedure. Only partial resection of the sella tumor could
be performed because of the difficult approach and exces¬
sive intraoperative bleeding. The histopathological exami¬
nation yielded a highly differentiated adenocarcinoma with
colloid containing follicles; there were no signs of increased
proliferative activity. Immunostaining was negative for
adrenocorticotrophic hormone (ACTH), growth hormone(GH), follicle-stimulating hormone (FSH), luteinizing hor¬
mone (LH), prolactin, and TSH, but positive for thy-
roglobulin, leading to the diagnosis of thyroid cancer
metastasis.
The patient was referred to the nuclear medicine de¬
partment to evaluate the possibility of radioiodine therapy.
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FIG. 1. Sagittal Tl-weighted magnetic resonance imaging(MRI) of the skull after intravenous administration of gadolin¬
ium. The tumor in the sella region is approximately 5 cm in
diameter, shows inhomogeneous contrast enhancement, and
destroys the sella walls and clivus. The ethmoidal cells are full
of tumor tissue, the cavernous sinuses are infiltrated, and the
optic chiasm is highly compressed (not distinguishable).
The thyroglobulin (hTG) level in serum (as measured by
125I immunoradiometric assay (IRMA) and validated by
recovery test) was 3681 ng/mL. Sonography of the neck
region showed 3 mL of thyroid remnant tissue on the left
side and none on the right. A whole-body scintigraphy with
99mTc-sestamibi revealed significant tracer accumulation
in the sella and some activity in the thyroid region, due
to remnant tissue (Fig. 2). A whole-body positron emission
tomography with 18fluorodeoxyglucose (18FDG-PET)
showed an increased glucose metabolism in the sella tu¬
mor without evidence of any other suspicious regions; the
thyroid bed region particularly, showed no pathological
finding. Hence, the sella tumor represented the only local¬
ization of malignancy. Because of the poor clinical condi¬
tion of the patient, we decided not to perform an ablative
large-dose radioiodine therapy initially, but rather first to
check the radioiodine uptake in the sella tumor. Because
the radioiodine test requires high TSH levels and the pa¬
tient failed to produce endogenous TSH, we applied rhTSH(Thyrogen™, Genzyme B.V., Naarden, NL) 0.9 mg intra¬
muscularly 48 hours and 24 hours prior to radioiodine ad¬
ministration after having obtained written informed con¬
sent. The result was an increase of the TSH level (in serum,
as measured by 125I-IRMA) from 0.16 to 237 mU/L 24
hours after the first rhTSH administration; after 48 hours,
following this first administration (24 hours after the sec¬
ond), TSH was 230 mU/L. Serum h-TG increased in par¬
allel to 4166 and its maximum value of 6626 ng/mL 24
and 48 hours after the first rhTSH administration. No side
effects occurred. For the radioiodine test, 2 mCi (74 MBq)
of 131I were given intravenously. In the probe measure¬
ment, the thyroid showed an uptake of 8% after 24 hours.
In contrast, the radioiodine uptake in the sella tumor was
less than 0.5% after 24 hours. Therefore, no significant tu¬
mor doses could be expected from radioiodine therapy.
Consequently, the patient was treated by external radi¬
ation of the sella region with 23 MV photon beam ther¬
apy up to a total dose of 45 Gy. Thyroxine substitution
and hydrocortisone therapy was begun. After 4 months,
clinical examination, MRI and 99mTc-sestamibi scintigra¬
phy showed stable disease; hTG had decreased to 574
ng/mL.
DISCUSSION
The pituitary gland is a relatively uncommon site for sec¬
ondary involvement in patients who died from dissemi¬
nated metastatic cancer (5). As reliable radiographie or
clinical distinction between a pituitary metastasis and pri¬
mary adenoma is not possible, surgical exploration for
biopsy and decompression is essential, unless precluded by
Table 1. Anterior Pituitary Stimulation Tests
Pretest Normal range 0 minutes
Test
15 minutes 30 minutes 60 minutes
Expected
increase Units
Estradiol
FT3
FT4
TSH
ACTH
Cortisol
LH
FSH
hGH
Prolactin
6.9
1.28
0.52
0.2
<5.0
2.5
<0.1
0.7
0.2
91.9
<46
2.0-5.1
0.9-1.9
0.27-4.2
9-52
8-25
>15
>15
<3
3.9-27.7
0.2
<5.0
2.1
<0.1
0.7
0.2
79.2
49
2.2
0.28
79
5.6
<0.1
1.2
2.2
78
7.3
0.1
1.7
5.8
92.7
3-25
>7
X 2
x 1.5
>10
pg/mL
pg/mL
ng/dL
mU/L
pg/mL
Mg/dL
IU/L
IU/L
ng/mL
ng/mL
For her anterior pituitary stimulation tests, the patient was given 50 µg of GHRH (GHRH Ferring, Ferring), 100 µg of CRH (CRH Ferring,
Ferring), and 100 ¡x% of GnRH (Relefact LH-RH, Hoechst) intravenously at 9:40 a.m
.
The next day, at 9:00 a.m., the patient was given 200 ¿u,g
of TRH (Antepan, Henning) intravenously. Detailed stimulation test results are given (all in serum).
FT3, free triiodothyronine; FT4, free thyroxine; TSH, thyrotropin; ACTH, adrenocorticotrophic hormone; LH, luteinizing hormone; FSH,
follicle stimulating hormone; hGH, human growth hormone.
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FIG. 2. Anterior 99mTc-sestamibi scintigraphy showing in¬
creased uptake in the sella tumor. Note normal uptake in sali¬
vary glands and thyroid remnant.
widespread coexistent disease (5). In this case, the mass
might have been an aggressive pituitary adenoma that had
dedifferentiated and begun to display thyroid morpholog¬
ical features; one might argue that there is no pathologi¬
cal evidence that this patient had a primary thyroid carci¬
noma. It is true that a primary thyroid cancer cannot be
proven because it has probably been removed during one
of the preceding operations, and it was impossible to gather
the pertinent information in Kazakhstan. In contrast to
this, not only the histopathological examination of sella
tumor tissue yielded morphological features of thyroid tis¬
sue, but moreover, immunostaining was positive for hTG,
leading to the diagnosis of a thyroid cancer metastasis.
Thyroid cancer is well known to metastasize to the lungs
and bones, whereas the brain is involved in only l%-2%(6,7). The brain as the only distant metastatic site was iden¬
tified in less than 0.1% of thyroid cancer patients (7). With
respect to the pituitary gland, there are only few reports
with documentation of métastases from carcinoma of the
thyroid (8-11). As known from cancers other than thyroid,
a metastasis to the sella turcica may even be the first and
only manifestation of an otherwise unknown cancer (5).
To our knowledge, this is the first report of a huge single
thyroid cancer metastasis in the sella region without evi¬
dence of further métastases, as shown by positron emis¬
sion tomography (PET).
Thyroid cancer with affinity to iodine should be treated
with radioiodine; the iodine uptake correlates with the dif¬
ferentiation grade and prognosis of the tumor (1). Because
the tumor tissue in the present case was well differentiated,
a significant radioiodine uptake was expected. The tumor
proved to exert high 18FDG- and 99mTc-sestamibi uptake
that may agree with either negative or positive results for
the radioiodine test (12). Together with the histological
findings, there was a chance for a positive radioiodine test
that would have led to radioiodine therapy as the best ther¬
apeutic option for this patient.
One might argue that we should have used a therapeu¬
tic dose of 131I to assess whether the metastasis was able
to take up radioiodine for two reasons. First, in case of a
rather large thyroid residue, it is not unusual that a con¬
comitant metastasis does not take up enough radioiodine
to be visualized and treated, so one should first ablate the
thyroid remnant before assuming that a metastasis is not
able to take up radioiodine. Second, diagnostic doses of
131I may not be sufficient to visualize métastases with low-
iodine avidity, while they can be better detected by the ad¬
ministration of therapeutic doses followed by whole body
scans (6,13,14). We were aware of these facts, but our case
was particularly different in some instances. First, the
metastasis volume exceeded the thyroid residue, which was
rather small. Second, we did not perform a whole-body
scan, but rather, performed probe measurements, which
are much more sensitive. Third, the patient was in such
poor clinical condition that only the least possible burden
of diagnostic or therapeutic procedures was tolerable and
appropriate. Fourth, in this case, we used 2 mCi of 131I in¬
travenously as the diagnostic dose, which is much more
than the usual test dose of 0.1 mCi given orally. This was
done to yield a better diagnostic sensitivity within a low-
dose diagnostic range. Due to the German radiation pro¬
tection laws, higher activities could not be applied on an
outpatient basis. As long as it was uncertain that the pa¬
tient would receive radioiodine therapy, we wanted her to
be studied on an outpatient basis. Finally, during the test,
the thyroid remnant showed an uptake of only 8%, so there
was 92% remaining for uptake in the large sella tumor,
which was less than 0.5%.
A main prerequisite for a positive radioiodine test (and
thus an effective therapy) are elevated basal TSH-levels.
This is usually achieved by thyroxine withdrawal, which
has two main side effects: severe symptomatic hypothy¬
roidism and stimulation of tumor cell growth due to per¬
sistent increased TSH release (1,2). Recombinant human
thyrotropin (rhTSH) was developed mainly to raise the
TSH level without thyroxine withdrawal (3,15). In our pa¬
tient, rhTSH became necessary because of hypopituitarism
due to her sella metastasis. We performed the rhTSH test
according to the modalities described in the literature (3,4);
in these studies, a significant increase of the TSH levels was
achieved, and the radioiodine scans were mostly compa¬
rable to those achieved in hypothyroidism. In our patient,
a significant increase of the TSH level was achieved as well.
The increase of the hTG level was also as expected from
the literature (3,4). With respect to rhTSH application in
the combination of metastatic thyroid cancer and sec¬
ondary hypothyroidism, there are few other reports in the
literature (16-18), but none of these cases had a sella
metastasis causing their hypopituitarism.
Unfortunately, there was not sufficient radioiodine up¬
take in our patient's sella tumor. This is consistent with
the finding that particularly 18FDG- and 99mTc-ses-
tamibi-positive tumors are frequently radioiodine negative(12). In that study population, there was another tendency
that 18FDG-positive and radioiodine-negative tumors were
encountered in high-grade tumors, whereas radioiodine-
positive and 18FDG-negative tumors were found in low-
grade carcinomas, although no statistical significance could
be reached (12). The presented case (18FDG- and 99mTc-
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sestamibi-positive, radioiodine-negative, but highly differ¬
entiated tumor tissue) did not meet all of these criteria.
Fortunately, the disease was stable after external photon
beam therapy, and the h-TG level had even decreased.
This case illustrates two major points. When con¬
fronted with a large sella tumor, the physician should be
aware of the possibility of a pituitary metastasis, although
this is an uncommon sequelae of cancer. A metastasis to
the sella turcica may even be the first and only manifes¬
tation of an otherwise unknown cancer. Of course, for
thyroid cancer, this is extremely rare. In a case of the
combination of thyroid cancer and failure to generate en¬
dogenous TSH, the use of rhTSH may permit an effective
radioiodine test.
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